Revealing the roles of TLR7, a nucleic acid sensor for COVID-19 in pan-cancer
暂无分享,去创建一个
Jialiang Yang | Z. Huang | Yuanyuan Han | Can Yang | Shixiong Li | Yaoxin Gao | Jingwen Yang | Qiuyan Huang | Decong Zhou
[1] W. Greenleaf,et al. Single-cell transcriptomic landscape of the developing human spinal cord , 2023, Nature Neuroscience.
[2] Daniele Di Mauro,et al. UBE2L3 regulates TLR7-induced B cell autoreactivity in Systemic Lupus Erythematosus. , 2023, Journal of autoimmunity.
[3] M. Amacker,et al. A low dose of RBD and TLR7/8 agonist displayed on influenza virosome particles protects rhesus macaque against SARS-CoV-2 challenge , 2023, Scientific Reports.
[4] Geng Tian,et al. ICSDA: a multi-modal deep learning model to predict breast cancer recurrence and metastasis risk by integrating pathological, clinical and gene expression data , 2022, Briefings Bioinform..
[5] Ju Xiang,et al. DGHNE: network enhancement-based method in identifying disease-causing genes through a heterogeneous biomedical network , 2022, Briefings Bioinform..
[6] Geng Tian,et al. Predicting colorectal cancer tumor mutational burden from histopathological images and clinical information using multi-modal deep learning , 2022, Bioinform..
[7] J. Wang,et al. Adjuvant-Protein Conjugate Vaccine with Built-In TLR7 Agonist on S1 Induces Potent Immunity against SARS-CoV-2 and Variants of Concern , 2022, ACS infectious diseases.
[8] G. Morahan,et al. Cancer susceptibility genes: update and systematic perspectives , 2022, Innovation (Cambridge (Mass.)).
[9] S. Soliman,et al. COVID-19 susceptibility, severity, clinical outcome and Toll-like receptor (7) mRNA expression driven by TLR7 gene polymorphism (rs3853839) in middle-aged individuals without previous comorbidities , 2022, Gene Reports.
[10] Masahiro Wakao,et al. Glyco-Nanoadjuvants: Impact of Linker Length for Conjugating a Synthetic Small-Molecule TLR7 Ligand to Glyco-Nanoparticles on Immunostimulatory Effects. , 2022, ACS chemical biology.
[11] J. Wang,et al. Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine , 2022, Frontiers in Immunology.
[12] Xiangxiang Zeng,et al. A weighted bilinear neural collaborative filtering approach for drug repositioning , 2022, Briefings Bioinform..
[13] Geng Tian,et al. Prediction of HER2-positive breast cancer recurrence and metastasis risk from histopathological images and clinical information via multimodal deep learning , 2021, Computational and structural biotechnology journal.
[14] Ping Li,et al. Deep-Tissue Fluorescence Imaging Study of Reactive Oxygen Species in a Tumor Microenvironment. , 2021, Analytical chemistry.
[15] A. Khalifa,et al. Potential value of pharmacological agents acting on toll-like receptor (TLR) 7 and/or TLR8 in COVID-19 , 2021, Current Research in Pharmacology and Drug Discovery.
[16] R. Rizzo,et al. TLR3 and TLR7 RNA Sensor Activation during SARS-CoV-2 Infection , 2021, Microorganisms.
[17] Tao Huang,et al. Genomic variation, origin tracing, and vaccine development of SARS-CoV-2: A systematic review , 2021, The Innovation.
[18] S. Ludovisi,et al. Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study , 2021, eLife.
[19] Xiaoping Wu,et al. Landscape Profiling Analysis of DPP4 in Malignancies: Therapeutic Implication for Tumor Patients With Coronavirus Disease 2019 , 2021, Frontiers in Oncology.
[20] Lijun Cai,et al. Indicator Regularized Non-Negative Matrix Factorization Method-Based Drug Repurposing for COVID-19 , 2021, Frontiers in Immunology.
[21] Jialiang Yang,et al. An Improved Anticancer Drug-Response Prediction Based on an Ensemble Method Integrating Matrix Completion and Ridge Regression , 2020, Molecular therapy. Nucleic acids.
[22] A. Oza,et al. COVID-19 Testing in Patients with Cancer: Does One Size Fit All? , 2020, Clinical Cancer Research.
[23] Chenqi Xu,et al. Immune checkpoint signaling and cancer immunotherapy , 2020, Cell Research.
[24] G. Superti-Furga,et al. TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7-9 , 2020, Nature.
[25] K. Farsalinos,et al. Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19 , 2020, Environmental Research.
[26] H. Kourie,et al. Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence , 2020, Critical Reviews in Oncology/Hematology.
[27] G. Onder,et al. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. , 2020, JAMA.
[28] Ruchong Chen,et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.
[29] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[30] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[31] J. Rehwinkel,et al. Deoxyguanosine is a TLR7 agonist , 2019, European journal of immunology.
[32] Adrian V. Lee,et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics , 2018, Cell.
[33] Russell Bonneville,et al. Landscape of Microsatellite Instability Across 39 Cancer Types. , 2017, JCO precision oncology.
[34] Toshiyuki Shimizu,et al. Structural Analysis Reveals that Toll-like Receptor 7 Is a Dual Receptor for Guanosine and Single-Stranded RNA. , 2016, Immunity.
[35] G. Getz,et al. Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.
[36] Gabriele Schackert,et al. DNA methylation profiles of long- and short-term glioblastoma survivors , 2013, Epigenetics.
[37] Guangchuang Yu,et al. clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.
[38] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[39] Thomas Lengauer,et al. A DNA methylation fingerprint of 1628 human samples. , 2011, Genome research.
[40] C. Schmitz,et al. Dual or triple activation of TLR7, TLR8, and/or TLR9 by single-stranded oligoribonucleotides. , 2011, Nucleic acid therapeutics.
[41] Rajeev Kumar,et al. Receiver operating characteristic (ROC) curve for medical researchers , 2011, Indian pediatrics.
[42] Gary D. Bader,et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function , 2010, Nucleic Acids Res..
[43] Shizuo Akira,et al. Signaling to NF-?B by Toll-like receptors , 2007 .
[44] L. Parker,et al. Translational Mini‐Review Series on Toll‐like Receptors: Networks regulated by Toll‐like receptors mediate innate and adaptive immunity , 2007, Clinical and experimental immunology.
[45] Shizuo Akira,et al. Signaling to NF-kappaB by Toll-like receptors. , 2007, Trends in molecular medicine.
[46] Shizuo Akira,et al. Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA , 2004, Science.
[47] Jongdae Lee,et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7 , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[48] A. Feinberg,et al. Hypomethylation distinguishes genes of some human cancers from their normal counterparts , 1983, Nature.